Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-03-27 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
2023年年度报告业绩说明会预告公告
Investor Presentation Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2023 Annual Report. It references the actual 2023 Annual Report and its summary, which were previously disclosed, and invites investors to participate in a webcast meeting to discuss the report. The document itself does not contain the full annual report or detailed financial data but serves as an announcement for the upcoming investor presentation event. According to the 'MENU VS MEAL' rule, this is not the report itself but an announcement related to the report. The best fitting category is 'Investor Presentation' (IP), as it details the upcoming presentation for investors focusing on financials and company performance.
2024-03-27 Chinese
董事会关于独立董事2023年度保持独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a formal announcement from the board of directors regarding the independence status of the company's independent directors for the year 2023. It references regulatory guidelines from the China Securities Regulatory Commission and the Beijing Stock Exchange concerning independent directors' independence. The content focuses on compliance and governance related to board members' independence, without financial data or report attachments. The document length is short (690 characters), and it is a specific governance-related statement rather than a full report or financial disclosure. Therefore, it fits best under Governance Information (CGR).
2024-03-19 Chinese
关于使用闲置自有资金购买理财产品公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Inner Mongolia Datang Pharmaceutical Co., Ltd. regarding the use of idle own funds to purchase financial products. It details the purpose, amount, duration, decision-making process, risk assessment, and impact on the company. The document is relatively short (1085 characters) and does not contain financial statements or detailed financial data. It is an update on a financing-related activity but not a full capital or financing report. It is not a report publication announcement or certification. The content fits best under Capital/Financing Update (CAP) as it informs about the company's financing activity involving investment of idle funds in financial products.
2024-03-19 Chinese
关于2024年度向银行等金融机构申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about its plan to apply for a comprehensive credit facility from banks and financial institutions for the year 2024. It includes details about the credit amount, board meeting approval, voting results, and authorization for management to handle the credit arrangements. There are no financial statements, earnings data, or detailed financial analysis present. The document is focused on financing activities and capital structure changes. Given the content and purpose, this fits the category of Capital/Financing Update (CAP). The document length is short and it is not merely announcing a report publication but providing substantive information about financing plans.
2024-03-19 Chinese
拟续聘2024年度会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (Da Hua CPA Firm) for the 2024 audit of Inner Mongolia Datang Pharmaceutical Co., Ltd. It details the firm's background, audit fees, independence, and the board and audit committee's approval of the proposal. There is no actual audit report or financial statements included, only information about the audit firm and the reappointment process. The document is relatively short (2902 characters) and serves as a formal announcement of the audit firm appointment rather than the audit report itself. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit information but is not a full annual report or audit report document. The confidence is high given the clear focus on audit firm appointment and audit-related disclosures. FY 2024
2024-03-19 Chinese
会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (auditor) for the year 2023. It discusses the auditor's qualifications, independence, audit procedures, and the company's assessment of the auditor's work. It does not contain the actual audited financial statements or detailed financial data but rather an assessment of the auditor's performance and compliance with regulations. The document length is short (1331 characters), and it is a standalone report about the audit firm's performance, not the full audit report or annual report itself. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and evaluations of audit firms' performance, excluding full annual reports. FY 2023
2024-03-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.